BTIG analyst Ryan Zimmerman has maintained their neutral stance on VCEL stock, giving a Hold rating on April 2.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ryan Zimmerman has given his Hold rating due to a combination of factors tied to both the new BARDA contract and Vericel’s overall positioning. The 10‑year, up to $197M NexoBrid agreement strengthens the burn care franchise, validates the product’s role in U.S. emergency preparedness, and is expected to add incremental revenue and cost offsets that enhance profitability over time.
However, NexoBrid’s commercial ramp has been slower than initially hoped, with modest recent sales despite broader center adoption, and much of the BARDA value remains milestone‑dependent and back‑end loaded. At the same time, Vericel’s shares already trade at a premium multiple versus peers, while its projected multi‑year revenue growth lags the group, leading Zimmerman to see the current valuation as fairly reflecting its risk and reward profile, rather than offering a compelling entry point.
In another report released on April 2, TipRanks – xAI also reiterated a Hold rating on the stock with a $34.00 price target.